Your browser doesn't support javascript.
loading
Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus
Thiruselvam Viswanathan; Shailee Arya; Siu-Hong Chan; Shan Qi; Nan Dai; Robert A Hromas; Jun-Gyu Park; Fatai Oladunni; Luis Martinez-Sobrido; Yogesh K Gupta.
Afiliación
  • Thiruselvam Viswanathan; University of Texas Health San Antonio, TX, USA
  • Shailee Arya; University of Texas Health San Antonio, TX, USA
  • Siu-Hong Chan; New England Biolabs, MA, USA
  • Shan Qi; University of Texas Health San Antonio, TX, USA
  • Nan Dai; New England Biolabs, MA, USA
  • Robert A Hromas; University of Texas Health San Antonio, TX, USA
  • Jun-Gyu Park; Texas Biomedical Research Institute, San Antonio, TX, USA
  • Fatai Oladunni; Texas Biomedical Research Institute, San Antonio, TX, USA
  • Luis Martinez-Sobrido; Texas Biomedical Research Institute, San Antonio, TX, USA
  • Yogesh K Gupta; University of Texas Health San Antonio, TX, USA
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-061705
ABSTRACT
The novel severe acute respiratory syndrome coronoavirus-2 (SARS-CoV-2), the causative agent of COVID-19 illness, has caused over 2 million infections worldwide in four months. In SARS coronaviruses, the non-structural protein 16 (nsp16) methylates the 5-end of virally encoded mRNAs to mimic cellular mRNAs, thus protecting the virus from host innate immune restriction. We report here the high-resolution structure of a ternary complex of full-length nsp16 and nsp10 of SARS-CoV-2 in the presence of cognate RNA substrate and a methyl donor, S-adenosyl methionine. The nsp16/nsp10 heterodimer was captured in the act of 2-O methylation of the ribose sugar of the first nucleotide of SARS-CoV-2 mRNA. We reveal large conformational changes associated with substrate binding as the enzyme transitions from a binary to a ternary state. This structure provides new mechanistic insights into the 2-O methylation of the viral mRNA cap. We also discovered a distantly located ligand-binding site unique to SARS-CoV-2 that may serve as an alternative target site for antiviral development.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2020 Tipo del documento: Preprint